1) Robinson PC, van der Linden S, Khan MA, et al. Axial spondyloarthritis:concept, construct, classification and implications for therapy. Nat Rev Rheumatol 2021;17(2):109-18.
2) van der Heijde D, Molto A, Ramiro S, et al. Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’:time to embrace the ASAS-defined nomenclature. Ann Rheum Dis 2023:ard-2023-225185. Online ahead of print. doi:10.1136/ard-2023-225185.
3) Tada K, Dobashi H, Taniguchi Y, et al. A multicentre study of clinical features and HLA typing in Japanese patients with ankylosing spondylitis. Mod Rheumatol 2023;33(2):392-7.
4) Matsubara Y, Nakamura Y, Tamura N, et al. A nationwide questionnaire survey on the prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis in Japan. Mod Rheumatol 2022;32(5):960-7.
5) Bohn R, Cooney M, Deodhar A, et al. Incidence and prevalence of axial spondyloarthritis:methodologic challenges and gaps in the literature. Clin Exp Rheumatol 2018;36(2):263-74.
6) Simone D, Al Mossawi MH, Bowness P. Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatology (Oxford) 2018;57(suppl_6):vi4-vi9. doi:10.1093/rheumatology/key001.
7) Yang X, Garner LI, Zvyagin IV, et al. Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides. Nature 2022;612(7941):771-7.
8) Hayashi E, Chiba A, Tada K, et al. Involvement of mucosal-associated invariant T cells in ankylosing spondylitis. J Rheumatol 2016;43(9):1695-703.
9) Poddubnyy D, Sieper J. Mechanism of new bone formation in axial spondyloarthritis. Curr Rheumatol Rep 2017;19(9):55. doi:10.1007/s11926-017-0681-5.
10) Kaaij MH, van Tok MN, Blijdorp IC, et al. Transmembrane TNF drives osteoproliferative joint inflammation reminiscent of human spondyloarthritis. J Exp Med 2020;217(10):e20200288. doi:10.1084/jem.20200288.